Takeda Pharmaceutical (TAK) Stock Analysis

Company Profile

Takeda Pharmaceutical (TAK) trades as an ADR rather than ordinary local shares — read it with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Takeda Pharmaceutical (TAK) posts ROE of 0.56%, roughly around the peer group’s normal range. Shareholders’ equity is producing a return that looks broadly typical for the industry.

Takeda Pharmaceutical (TAK) keeps 0.87% of revenue as net profit, roughly in line with the peer group’s normal net margin range. Its full cost stack is taking a typical share of sales for the industry.

Takeda Pharmaceutical (TAK) turns 24.55% of revenue into operating profit, putting operating margin in the upper peer quartile. Before financing and taxes enter the picture, the day-to-day business keeps more of each sales dollar than most industry peers.

Profitability Metrics

Growth

Takeda Pharmaceutical (TAK) grew revenue -1.66%, in the lower peer quartile. The top line is expanding more slowly than at most peers, which can reflect softer demand, lost share, or weaker pricing.

Takeda Pharmaceutical (TAK) grew earnings per share 77.96%, in the upper peer quartile. Per-share profits are compounding faster than at most industry peers.

Growth Metrics

Financial Strength

Takeda Pharmaceutical (TAK) has current ratio of 1.15, in the tighter-liquidity quartile for its industry. The short-term cushion is thinner than most peers carry, even if the absolute comfort level still depends on the business model.

Takeda Pharmaceutical (TAK) has debt-to-equity ratio of 0.72, in the higher-leverage quartile for its industry. The heavier reliance on borrowing can make earnings, rates, or refinancing conditions matter more.

Financial Strength Metrics

Dividends

Takeda Pharmaceutical (TAK) has dividend yield of 953.28%, above the entire industry range. That headline income is large, but yields this far above peers often come from a falling share price or an at-risk payout, so dividend safety matters more than the percentage itself.

Takeda Pharmaceutical (TAK) has payout ratio of 426.53%, meaning dividends exceeded current-period earnings. The gap would need to be covered by cash, retained earnings, financing, or other sources, so earnings alone do not support the payout.

Dividend Metrics

Valuation

Takeda Pharmaceutical (TAK) trades at P/E ratio of 300.29, above the peer range for its industry. The market is paying unusually heavily for TTM earnings relative to comparable companies.

Takeda Pharmaceutical (TAK) trades at 0.01 on P/S ratio, in the lower sales-valuation quartile for its industry. That points to a cheaper revenue stream than most peers, with margin quality still doing the heavy lifting.

Takeda Pharmaceutical (TAK) trades at 1.43 on P/B ratio, in the lower book-value quartile for its industry. Investors are paying less for the balance-sheet equity than they pay for most peers, with returns on that equity still central to the read.

Valuation Metrics